Cytokinetics Q4 2023 GAAP EPS $(1.38) Misses $(0.97) Estimate, Sales $1.67M Miss $10.77M Estimate
Portfolio Pulse from Benzinga Newsdesk
Cytokinetics reported Q4 2023 GAAP EPS of $(1.38), missing the $(0.97) estimate, with sales of $1.67M also missing the $10.77M estimate. This represents a significant miss on both earnings and revenue expectations, with a 14.56% decrease in sales compared to the same period last year.
February 27, 2024 | 9:11 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Cytokinetics missed Q4 2023 earnings and revenue estimates significantly, with a 14.56% decrease in sales year-over-year.
Missing both earnings and revenue estimates by wide margins indicates operational challenges and could lead to negative investor sentiment in the short term. The significant miss on revenue, coupled with a year-over-year decrease in sales, suggests potential underlying issues that could impact the stock price negatively.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100